PEG-MGF
PEGylated Mechano Growth Factor
PEG-MGF is a peptide people usually talk about for Muscle Wasting and Sarcopenia: Potential to counteract age-related muscle loss and wasting diseases by replenishing the satellite cell pool. and Injury Repair: Accelerating recovery from severe muscle, tendon, and ligament injuries.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Why does this matter?
PEG-MGF matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.
Molecular weight
Approximately 2867.2 g/mol to 2888.16 Da (for the peptide portion). The total molecular weight can vary depending on the length of the PEG chain, often reaching 6-8 kDa in total.
Molecular formula
Not specified in the source research
Amino acid count
24
Review date
Before February 2027
Sequence / structure
PEG-MGF consists of the IGF-1Ec splice variant (the unique E-domain of MGF) with a polyethylene glycol (PEG) chain attached to protect it from rapid enzymatic breakdown.
Other names
PEG-MGF, Pegylated Mechano Growth Factor, Pegylated IGF-1Ec, Pegylated MGF
Status
Under FDA review for muscle growth and repair
PEG-MGF is a muscle-repair peptide built to stay active much longer than the body’s natural mechano growth factor. People usually talk about it for injury recovery, rebuilding damaged muscle, and protecting against age-related muscle loss because it helps activate the stem cells involved in repair. That longer-lasting repair signal is what made PEG-MGF so popular in recovery and physique circles.
The quick version before the deep dive
- •People usually talk about PEG-MGF for Muscle Wasting and Sarcopenia: Potential to counteract age-related muscle loss and wasting diseases by replenishing the satellite cell pool. and Injury Repair: Accelerating recovery from severe muscle, tendon, and ligament injuries..
- •Injury Repair: Accelerating recovery from severe muscle, tendon, and ligament injuries.
- •Upon muscle injury or mechanical stress, MGF is locally expressed and signals satellite cells to multiply (proliferate).
- •Unlike mature IGF-1, which causes these cells to differentiate and fuse into mature muscle fibers, MGF specifically Helps promote their proliferation while inhibiting terminal differentiation. This expands the pool of available stem cells for repair.
Deep Dive: Mechanism of Action +
Satellite Cell Activation and Proliferation: Upon muscle injury or mechanical stress, MGF is locally expressed and signals satellite cells to multiply (proliferate).
Differentiation Inhibition: Unlike mature IGF-1, which causes these cells to differentiate and fuse into mature muscle fibers, MGF specifically promotes their proliferation while inhibiting terminal differentiation. This expands the pool of available stem cells for repair.
Independent Pathway: Evidence suggests that MGF exerts these effects through a receptor-independent mechanism, distinct from the classical IGF-1 receptor pathway used by systemic IGF-1.
Where people usually see it discussed
Investigated Applications +
- Muscle Wasting and Sarcopenia: Potential to counteract age-related muscle loss and wasting diseases by replenishing the satellite cell pool.
- Injury Repair: Accelerating recovery from severe muscle, tendon, and ligament injuries.
- Cardiac Repair: Investigated for protective and regenerative effects following ischemic damage to the heart (e.g., post-myocardial infarction).
- Bone Healing: Emerging research suggests potential roles in stimulating osteoblasts and promoting fracture healing.
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
Currently, PEG-MGF is primarily considered a research chemical and lacks extensive, large-scale human clinical trial data. Most studies involving MGF and PEG-MGF have been conducted in vitro (cell cultures) or in vivo in animal models (rodents). While early research generated significant interest from pharmaceutical companies for treating conditions like muscular dystrophy and sarcopenia, formalized Phase II/III clinical trials for PEG-MGF specifically have not progressed to widespread human therapeutic approval.
Phase IIMuscle growth and repair
Currently, PEG-MGF is primarily considered a research chemical and lacks extensive, large-scale human clinical trial data. Most studies involving MGF and PEG-MGF have been conducted in vitro (cell cultures) or in vivo in animal models (rodents). While early research generated significant interest from pharmaceutical companies for treating conditions like muscular dystrophy and sarcopenia, formalized Phase II/III clinical trials for PEG-MGF specifically have not progressed to widespread human therapeutic approval.
What the current safety discussion looks like
- ✓Observed Side Effects: In experimental settings, reported side effects include localized swelling at the injection site, transient drops in blood sugar, changes in blood pressure, and potential for irregular heart rate.
- ✓Relationship to IGF-1 System: While MGF acts independently of the main IGF-1 receptor, its potent growth-promoting effects raise theoretical concerns similar to other growth factors, such as the potential to inadvertently stimulate the growth of existing abnormal cells.
- ✓Immunogenicity: The addition of the PEG chain, while extending half-life, can sometimes provoke an immune response (anti-PEG antibodies) in some subjects.
How the status timeline currently reads
Current status
Current Status: PEG-MGF is not approved by the FDA for human use. It was previously categorized by the FDA as a Category 2 bulk drug substance (September 2023), indicating significant safety concerns that limited compounding.
Current status
Updates: As of April 2026, PEG-MGF is slated for removal from the Category 2 list due to the withdrawal of its original nomination, lowering some regulatory barriers but not conferring approval.
Current status
Future Review: The FDA plans to consult its Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 to re-evaluate the status of PEG-MGF and determine its potential eligibility for compounding by licensed facilities.
How dosing is usually described
Route of Administration
Typically administered via subcutaneous (SubQ) or intramuscular (IM) injection.
Frequency
Due to the extended half-life provided by pegylation, research protocols often involve dosing 2 to 3 times per week, rather than daily.
Timing
In animal exercise models, it is frequently administered post-workout or on non-training recovery days to maximize its effect on the satellite cell proliferation phase.
Dosage Range
Experimental doses typically range in the microgram scale (e.g., 200mcg to 400mcg per administration), often administered bilaterally into target muscle groups in animal models.
Research protocols only. Not medical advice.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Goldspink, G. "(Multiple publications): Foundational research on the cloning of IGF-1 isoforms and the identification of MGF as a unique, exercise-induced splice variant." .
- 2
Yang, S. Y., & Goldspink, G. (2002):. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." 2002.
- 3
Hill, M., & Goldspink, G. (2003):. "Expression and splicing of the insulin-like growth factor gene in skeletal muscle." 2003.
Common questions about PEG-MGF
What is PEG-MGF? +
PEG-MGF is PEGylated Mechano Growth Factor, one of the peptides currently under review in connection with muscle growth and repair.
What is PEG-MGF being reviewed for? +
The current advisory review focuses on muscle growth and repair, with a listed review date of Before February 2027.
Which category does PEG-MGF belong to? +
PEG-MGF is grouped in this library under Recovery.
How many amino acids are in PEG-MGF? +
PEG-MGF is presented here as a 24-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for PEG-MGF? +
PEG-MGF consists of the IGF-1Ec splice variant (the unique E-domain of MGF) with a polyethylene glycol (PEG) chain attached to protect it from rapid enzymatic breakdown..
What research applications are most associated with PEG-MGF? +
Muscle Wasting and Sarcopenia: Potential to counteract age-related muscle loss and wasting diseases by replenishing the satellite cell pool., Injury Repair: Accelerating recovery from severe muscle, tendon, and ligament injuries., Cardiac Repair: Investigated for protective and regenerative effects following ischemic damage to the heart., and Bone Healing: Emerging research suggests potential roles in stimulating osteoblasts and promoting fracture healing.
How is PEG-MGF described as working in the current research? +
Upon muscle injury or mechanical stress, MGF is locally expressed and signals satellite cells to multiply (proliferate). Unlike mature IGF-1, which causes these cells to differentiate and fuse into mature muscle fibers, MGF specifically Helps promote their proliferation while inhibiting terminal differentiation. This expands the pool of available stem cells for repair.
How is PEG-MGF usually discussed in protocols or treatment plans? +
PEG-MGF is most often described with route of administration and frequency protocols in the source material.
What does the safety discussion say about PEG-MGF? +
Observed Side Effects: In experimental settings, reported side effects include localized swelling at the injection site, transient drops in blood sugar, changes in blood pressure, and potential for irregular heart rate. Relationship to IGF-1 System: While MGF acts independently of the main IGF-1 receptor, its potent growth-promoting effects raise theoretical concerns similar to other growth factors, such as the potential to inadvertently stimulate the growth of existing abnormal cells.
Continue the comparison
TB-500
TB-500 is a peptide people usually talk about for Chronic non-healing wounds and Surgical wound healing. It is still in the FDA review process, so people are watching both the research and the access question closely.
BPC-157
BPC-157 is a peptide people usually talk about for Ulcerative colitis and Inflammatory bowel disease. It is still in the FDA review process, so people are watching both the research and the access question closely.
MOTS-c
MOTS-c is a peptide people usually talk about for Obesity and Type 2 diabetes / insulin resistance. It is still in the FDA review process, so people are watching both the research and the access question closely.
Get notified when PEG-MGF becomes available
Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.